FENFLURAMINE FOR TREATMENT RESISTANT CONVULSIVE SEIZURES IN PATIENTS WITH FOXG1 MUTATIONS
Brief description of study
The purpose of this study is to enroll 10 patients, ages 2-35 years old, with a confirmed genetic/clinical diagnosis of FOXG-1 in an open label trial of fenfluramine for seizure control. Patients will be titrated over 14 days to a dose of ZX008 0.7 mg/kg/day (maximum dose 30 mg/d). Study objectives are decrease in seizure frequency and change in impression and quality of life
Clinical Study Identifier: s21-00387
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
